56443-24-4

Upstream product

• 582-24-1 1-phenyl-2-hydroxyethanone 
• 100-39-0 benzyl bromide 
• 118-93-4 o-hydroxyacetophenone 
• 31165-67-0 2'-benzyloxyacetophenone 
• 100-44-7 benzyl chloride 

Downstream Products

• 406212-34-8 1-[2-(benzyloxy)phenyl]-2-fluoroethanone 
• 142363-80-2 2-(2-hydroxyphenyl)-4-n-propylmorpholine 
• 744216-10-2 2'-amino-6'-(2-benzyloxy-phenyl)-3'-cyano-5'-fluoro-3,4,5,6-tetrahydro-2H-[3,4']bipyridinyl-1-carboxylic acid tert-butyl ester 
• 80151-37-7 1-(2-(benzyloxy)phenyl)pentane-1,4-dione 
• 856438-60-3 4-(2-(benzyloxy)phenyl)-4-oxobutanal 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR TREATING CANCER

Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of neuroblastoma, small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), large-cell carcinoma (LCC), squamous cell carcinoma (SqCC), and/o

COMPOSITIONS AND METHODS FOR TREATING CANCER

Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeuti

COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES

Provided herein are naphthylic derivative compounds, or pharmaceutically acceptable salts thereof, that are useful for inhibiting cancers. Also provided herein are methods of using effective amounts of said compounds, optionally with pharmaceutical carrie

Multifunctional heterocyclic scaffolds for hybrid Lewis acid/Lewis base catalysis of carbon–carbon bond formation

Several new classes of hybrid catalysts have been synthesized by tethering heterocyclic metal (Lewis acid) chelating scaffolds to several different amines capable of facilitating enamine catalysis. Oxazole, thiazole, and imidazole-based chiral precatalyst

A xanthate-based free radical approach to defucogilvocarcin M

A formal total synthesis of the aglycon of gilvocarcin M is described. The synthesis is based on the construction of the key naphthalene 7 via a free radical addition-cyclization protocol followed by aromatization of the resulting α-tetralone. This highly

AROYLFURANES AND AROYLTHIOPHENES

The invention relates to compounds of formula (I) and of formula (II) wherein ring A is a phenyl, pyridine, pyrimidine or pyrazine ring, W and X are carbon or nitrogen, Y is oxygen or sulfur, R0 is different from hydrogen, Rx is -(C=O)R1 or cyano; R1 is hydrogen, optionally substituted hydroxy or optionally substituted amino, and the other substituents are as described in the specification. The invention further relates to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I) and of formula (II), to the use of compounds of formula (I) and of formula (II) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I), of formula (II) or of pharmaceutical compositions containing same.

Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 2: Improvement of in vitro activity

A series of 2-amino-3-cyano-4-alkyl-6-(2-hydroxyphenyl)pyridine derivatives was synthesized and evaluated as IκB kinase β (IKK-β) inhibitors. Substitution of an aminoalkyl group for the aromatic group at the 4-position on the core pyridine ring resulted i

Pyridine derivatives

Pyridine compounds of general formula: wherein —R1represents in which R11is hydrogen, C1-6alkyl, halogen, hydroxy, C1-12alkoxy, nitro, amino, C1-6alkylsulfonylamino, C1-6alkoxycarbonyl, C1-6alkylamino, di(C1-6alkyl)amino, C1-6alkanoylamino, phenyl C1-6alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2represents hydrogen or halogen; R3represents hydrogen, —CR31R32R33, or —NR34R35; R4is hydrogen, carbamoyl, CN, carboxyl, etc.; R5is amino, C1-6alkylamino, di C1-6alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Tricyclic compounds and drug compositions containing the same

Compounds having a β-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2 NR4 R4', or nitro; R6 represents hydrogen or lower alkyl; and X represents nitrogen, R9 represents hydrogen, one of R7 and R8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

Oxygen Isosteric Derivatives of 3-(3-Hydroxyphenyl)-N-n-propylpiperidine

Some substituted 3-phenylmorpholines (10a-e,j,k) and 3-thienylmorpholines (10f,g), isosteres of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), were prepared and submitted to binding assays on D-2 dopaminergic and 5-HT1 and 5-HT2 serotonergic receptors, in comparison with 3-PPP and its analogue 3a,b.The results show the loss of D-2 affinity for all morpholines, while a certain activity was still observable for piperidine derivatives.Regarding the serotonergic affinity, only chloro and methoxy derivatives (10a-d) were moderately active on the 5-HT1A receptor, either when the substituent was in the C-2 or C-3 position, whereas no tested compounds showed affinity toward the 5-HT2 receptor.